Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

3
ESMO-MCBS v1.1
Scorecard version: 1

Indication details

Tumour Type
Thoracic Malignancies
Tumour Sub-type
Non-small-cell Lung Cancer
Tumour Sub-Group
EGFR+
Control Arm
Gefitinib
Treatment Setting
1st line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer
Trial Name
ARCHER 1050

Primary Outcome(s)

Primary Outcome(s)
PFS
Evaluated Outcome
OS
Form(s)
Form 2a

Outcome Data

PFS Control
9.2 months
PFS Gain
5.5 months
PFS HR
0.59 (0.47–0.74)
OS Control
26.8
OS Gain
7.3 months
OS HR
0.76 (0.58–0.99)
QoL Comment
No improvement
Toxicity Comment
Increased toxicity

Final Score (after adjustments)

Preliminary non-curative score
3
Final non-curative Score
3
Issue date
04.12.2019
Release date
04.12.2019

DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; mDoR, median duration of response; mPFS, median progression-free survival; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings